Tier 3 — preclinical

Urolithin A activates aryl hydrocarbon receptor-NLRP6-mediated pathways in intestinal epithelial cells to modulate mucosal immunity and strengthen gut barrier integrity

Ghosh S, Vanwinkle ZM, Bodduluri SR, Juin SK, Kadari M, Singh A, Dryden GW, Lawrenz MB, Kanneganti TD, Rai SN, Good M, Kumar P, Haribabu B, Jala VR
Nature Communications 2026 17(1):5411

Bibliography

PubMed
PMID 42336837
DOI
10.1038/s41467-026-73760-3

Study snapshot

DesignMechanistic translational study using mouse models, intestinal epithelial systems and human IBD intestinal biopsies
ModelMouse intestinal epithelium/colitis models and ex vivo human IBD intestinal biopsies
SampleMultiple experimental cohorts plus human biopsy samples
InterventionUrolithin A exposure with AHR/NLRP6 pathway interrogation
DurationVaried by model
EndpointsAHR activation; NLRP6 inflammasome signaling; IL-18 and IL-22; MUC2 and REG3γ; Intestinal barrier function; Experimental colitis protection

What the study showed, in plain terms

This 2026 Nature Communications paper links Urolithin A to a specific gut-barrier immune pathway: AHR activation, NLRP6 signaling, IL-18/IL-22 and mucin/antimicrobial barrier responses. Importantly, parts of the pathway were observed in intestinal biopsies from people with IBD, but the study did not test oral Urolithin A treatment outcomes in patients.

Key findings

Urolithin A activated epithelial AHR and NLRP6 signaling.

IL-18, IL-22, MUC2 and REG3γ responses supported barrier protection in experimental models.

Human IBD biopsy experiments showed increased IL-18 and IL-22-related responses.

The study gives a detailed mechanistic basis for a gut-barrier research cluster.

What this study can and cannot tell us

Human data were ex vivo biopsy experiments rather than a supplementation trial.

Experimental colitis protection was demonstrated in animal models.

Clinical symptom, remission or disease-modification outcomes were not tested.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology